From Wikipedia, the free encyclopedia
Chemical compound
Hyzetimibe
![](https://upload.wikimedia.org/wikipedia/commons/thumb/9/98/Hyzetimibe.svg/220px-Hyzetimibe.svg.png) |
|
Other names | HS-25 |
---|
|
Legal status |
- In general: ℞ (Prescription only)
|
---|
|
(3R,4S)-1-(4-Fluorophenyl)-3-((Z)-3-(4-fluorophenyl)-4-hydroxy-but-2-enyl)-4-(4-hydroxyphenyl)azetidin-2-one
|
CAS Number | |
---|
PubChem
CID | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEMBL | |
---|
|
Formula | C25H21F2NO3 |
---|
Molar mass | 421.444 g·mol−1 |
---|
InChI=InChI=1S/C25H21F2NO3/c26-19-6-1-16(2-7-19)18(15-29)5-14-23-24(17-3-12-22(30)13-4-17)28(25(23)31)21-10-8-20(27)9-11-21/h1-13,23-24,29-30H,14-15H2/b18-5+/t23-,24-/m1/s1 Key:HEHHPZYUXSFAPV-SMOXZEHUSA-N
|
Hyzetimibe is a pharmaceutical drug that
inhibits cholesterol absorption.
[1]
[2] It targets the
NPC1-like intracellular cholesterol transporter 1.
[2]
In China, it is used as a lipid-lowering agent and it has efficacy similar to
ezetimibe.
[3]
References
-
^ Ruan Z, Jiang B, Chen J, Zhang X, Lou H, Xiang M, et al. (October 2014). "Pharmacokinetics, pharmacodynamics, safety, and tolerability of hyzetimibe (HS-25) in healthy Chinese subjects". Journal of Clinical Pharmacology. 54 (10): 1144–1152.
doi:
10.1002/jcph.310.
PMID
24752831.
- ^
a
b Liao J, Yang L, Zhou L, Zhao H, Qi X, Cui Y, Ouyang D (2022).
"The NPC1L1 Gene Exerts a Notable Impact on the Reduction of Low-Density Lipoprotein Cholesterol in Response to Hyzetimibe: A Factorial-Designed Clinical Trial". Frontiers in Pharmacology. 13: 755469.
doi:
10.3389/fphar.2022.755469.
PMC
8963242.
PMID
35359877.
-
^ Li JJ, Zhao SP, Zhao D, Lu GP, Peng DQ, Liu J, et al. (2023).
"2023 Chinese guideline for lipid management". Frontiers in Pharmacology. 14: 1190934.
doi:
10.3389/fphar.2023.1190934.
PMC
10498001.
PMID
37711173.